Latest news
News
-
3 September 2021
Cosentyx (Secukinumab) - NICE approves biologic to treat psoriasis in children and young people
Cosentyx (Secukinumab) has been recommended for the treatment of severe psoriasis in children and young people (aged 6 to 17 years) in England and Wales.
-
2 September 2021
'Severely immunosuppressed' people to be offered third dose of COVID-19 vaccine
The JCVI has recommended that people who are 'severely immunosuppressed' should have a third dose of the COVID-19 vaccine, at least 8 weeks after the second dose.
-
1 September 2021
Bimzelx (Bimekizumab) - NICE approves new biologic for psoriasis
Bimzelx (Bimekizumab) has been recommended for the treatment of severe psoriasis in adults in England and Wales.
-
19 August 2021
Coronavirus (COVID-19) Information
Information for people living with psoriasis and psoriatic arthritis, including those taking immunosuppressive medicines.
-
19 August 2021
What is the latest 'shielding' guidance?
Advice for people who are deemed to be 'clinically extremely vulnerable'.